135 related articles for article (PubMed ID: 35744895)
21. The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.
Skoblar Vidmar M; Doma A; Smrdel U; Zevnik K; Studen A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743228
[TBL] [Abstract][Full Text] [Related]
22. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model.
Plengsuriyakarn T; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):293-304. PubMed ID: 25545782
[TBL] [Abstract][Full Text] [Related]
23. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
24. [IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
Ogawara Y; Kitabayashi I
Rinsho Ketsueki; 2015 Aug; 56(8):1045-52. PubMed ID: 26345565
[TBL] [Abstract][Full Text] [Related]
25. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA; Lin J; Diebold RB; Campbell AM; Ericsson A; Gustafson G; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Kershaw M; Yao L; Toms AV; Barr KJ; Dinsmore CJ; Walker D; Ashwell S; Lu W
J Med Chem; 2020 Feb; 63(4):1612-1623. PubMed ID: 31971798
[TBL] [Abstract][Full Text] [Related]
26. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
27. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
[TBL] [Abstract][Full Text] [Related]
28. PET and SPECT in low-grade glioma.
Minn H
Eur J Radiol; 2005 Nov; 56(2):171-8. PubMed ID: 16233891
[TBL] [Abstract][Full Text] [Related]
29. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
30. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
31. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
[TBL] [Abstract][Full Text] [Related]
32. The implications of IDH mutations for cancer development and therapy.
Pirozzi CJ; Yan H
Nat Rev Clin Oncol; 2021 Oct; 18(10):645-661. PubMed ID: 34131315
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
34. Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer.
Temma T; Nishigori K; Onoe S; Sampei S; Kimura I; Ono M; Saji H
Nucl Med Biol; 2015 Feb; 42(2):184-91. PubMed ID: 25457456
[TBL] [Abstract][Full Text] [Related]
35. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
36. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
37. Detection of recurrence in glioma: a comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT.
Santra A; Kumar R; Sharma P; Bal C; Julka PK; Malhotra A
Clin Nucl Med; 2011 Aug; 36(8):650-5. PubMed ID: 21716014
[TBL] [Abstract][Full Text] [Related]
38. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
Nakagawa M; Yamaguchi M; Endo M; Machida Y; Hattori A; Tanzawa F; Tsutsumi S; Kitabayashi I; Kawai A; Nakatani F
J Bone Oncol; 2022 Jun; 34():100430. PubMed ID: 35493690
[TBL] [Abstract][Full Text] [Related]
40. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]